Kyverna Therapeutics announced the designation as Regenerative Medicine Advanced Therapy by the U.S. FDA for its autologous, fully human CD19 chimeric antigen receptor T-cell product candidate, KYV-101, to be used for the treatment of patients suffering from progressive myasthenia gravis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
- JMP Securities healthcare analysts hold an analyst/industry conference call
- 3 Best Stocks to Buy Now, 7/18/2024, According to Top Analysts
- Kyverna RMAT designation positive for shares, says Leerink
- Kyverna Therapeutics’ KYV-101 Gains FDA Advanced Therapy Designation